En español
NIDA

Opioids

Knowing When to Say When: Transitioning Patients from Opioid Therapy

Summary

Uses a case study to teach when and how to taper and/or transition patients off opioid-based medications in primary care settings

Resource Materials

Details

Microneedle Milestone: One Week of Transdermal Drug Delivery

Microneedles are an innovative technique for delivering medications through the skin, a route that could particularly benefit patients receiving naltrexone therapy for opioid and alcohol dependence. Researchers have found a way to use the transdermal technique to deliver a single treatment of naltrexone that lasts for 7 days.

Naloxone—A Potential Lifesaver

Combating the epidemic of opioid abuse—including prescription painkillers and, increasingly, heroin—requires a multi-pronged approach that involves reducing drug diversion, expanding delivery of existing treatments (including medication-assisted treatments), and development of new medications for pain that can augment our existing treatment arsenal. But another crucial component we must not forget is that people who abuse or are addicted to opioids need to be kept alive long enough that they can be treated successfully. In this, the drug naloxone has a large potential role to play.

Another Reminder of the Terrible Toll of Addiction

Philip Seymour HoffmanEverett Collection / Shutterstock.com

This past weekend Americans were shocked and saddened to learn that one of our greatest actors, Philip Seymour Hoffman, had died at age 46 of an apparent heroin overdose. Hoffman’s death, in the prime of his life and career, is a poignant reminder of some of the harsh realities of a disease that 17.7 million Americans struggle with and that all too often cuts their lives short.

Dr. Evan D. Kharasch Joins the Institute of Medicine

Dr. Kharasch is a NIDA-funded researcher known for a broad range of research into how drugs are metabolized in the body.

Medications That Treat Opioid Addiction Do Not Impair Liver Health

A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

Naltrexone Implant Outperforms Daily Pill in Russian Trial

More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.

Dr. Marilyn Huestis Q & A: Matching Drug Effects to Drug Concentrations

Dr. Marilyn Huestis of NIDA’s Intramural Research Program talks about conducting research on drug effects with human subjects, developing tests to help law enforcement identify drugged drivers, and an assay to help identify children whose prenatal exposure to anti-HIV drugs may put them at risk for adverse developmental outcomes.

Oxycodone Vaccine Passes Early Tests

A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.

Pages